M J Piccart-Gebhart

Summary

Country: Belgium

Publications

  1. ncbi request reprint Randomized intergroup trial of cisplatin-paclitaxel versus cisplatin-cyclophosphamide in women with advanced epithelial ovarian cancer: three-year results
    M J Piccart
    European Organization for Research and Treatment of Cancer EORTC Gynecological Cancer Cooperative Group, EORTC Data Center, Brussels, Belgium
    J Natl Cancer Inst 92:699-708. 2000
  2. ncbi request reprint Intergroup collaboration in ovarian cancer: a giant step forward
    M J Piccart
    Institut Jules Bordet, Bruxelles, Belgium
    Ann Oncol 10:83-6. 1999
  3. ncbi request reprint Herceptin: the future in adjuvant breast cancer therapy
    M J Piccart-Gebhart
    Chemotherapy Unit, Institut Jules Bordet, Brussels, Belgium
    Anticancer Drugs 12:S27-33. 2001
  4. ncbi request reprint The predictive value of HER2 in breast cancer
    M Piccart
    Institut Jules Bordet, Brussels, Belgium
    Oncology 61:73-82. 2001
  5. ncbi request reprint HER2. a 'predictive factor' ready to use in the daily management of breast cancer patients?
    M J Piccart
    Institut Jules Bordet, Unite de Chimiotherapie, Rue Heger Bordet 1, B 1000, Brussels, Belgium
    Eur J Cancer 36:1755-61. 2000
  6. ncbi request reprint The impact of chemotherapy dose density and dose intensity on breast cancer outcome: what have we learned?
    M J Piccart
    Chemotherapy Unit, Department of Internal Medicine, Institut Jules Bordet, Association Hospitalière de Bruxelles, Centre des Tumeurs de l ULB, 1 rue Héger Bordet, B 1000, Brussels, Belgium
    Eur J Cancer 36:S4-10. 2000
  7. ncbi request reprint Oxaliplatin or paclitaxel in patients with platinum-pretreated advanced ovarian cancer: A randomized phase II study of the European Organization for Research and Treatment of Cancer Gynecology Group
    M J Piccart
    Institut Jules Bordet and European Organization for Research and Treatment of Cancer, Brussels, Belgium
    J Clin Oncol 18:1193-202. 2000
  8. doi request reprint Pertuzumab: new hope for patients with HER2-positive breast cancer
    M Capelan
    Department of Medicine, Institute Jules Bordet, l Université Libre de Bruxelles, Brussels, Belgium
    Ann Oncol 24:273-82. 2013
  9. doi request reprint Adjuvant chemotherapy--yes or no? Prognostic markers in early breast cancer
    M J Piccart-Gebhart
    Department of Medicine, Jules Bordet Institute, Brussels, Belgium
    Ann Oncol 18:xii2-7. 2007
  10. pmc Ki-67 as prognostic marker in early breast cancer: a meta-analysis of published studies involving 12,155 patients
    E de Azambuja
    Medical Oncology Clinic, Jules Bordet Institute, 125 Boulevard de Waterloo, 1000, Brussels, Belgium
    Br J Cancer 96:1504-13. 2007

Detail Information

Publications10

  1. ncbi request reprint Randomized intergroup trial of cisplatin-paclitaxel versus cisplatin-cyclophosphamide in women with advanced epithelial ovarian cancer: three-year results
    M J Piccart
    European Organization for Research and Treatment of Cancer EORTC Gynecological Cancer Cooperative Group, EORTC Data Center, Brussels, Belgium
    J Natl Cancer Inst 92:699-708. 2000
    ..Before considering the paclitaxel-cisplatin regimen as the new "standard," a group of European and Canadian investigators planned a confirmatory phase III trial...
  2. ncbi request reprint Intergroup collaboration in ovarian cancer: a giant step forward
    M J Piccart
    Institut Jules Bordet, Bruxelles, Belgium
    Ann Oncol 10:83-6. 1999
    ..A similar organisation as for breast cancer (Breast International Group, BIG) needs to be established for ovarian cancer...
  3. ncbi request reprint Herceptin: the future in adjuvant breast cancer therapy
    M J Piccart-Gebhart
    Chemotherapy Unit, Institut Jules Bordet, Brussels, Belgium
    Anticancer Drugs 12:S27-33. 2001
    ..This is particularly important given that HER2-positive breast cancer patients form a high-risk group with a poor overall prognosis...
  4. ncbi request reprint The predictive value of HER2 in breast cancer
    M Piccart
    Institut Jules Bordet, Brussels, Belgium
    Oncology 61:73-82. 2001
    ..Outside of clinical trials, adequately dosed anthracycline-based chemotherapy is the current preferred adjuvant treatment option for HER2-positive patients...
  5. ncbi request reprint HER2. a 'predictive factor' ready to use in the daily management of breast cancer patients?
    M J Piccart
    Institut Jules Bordet, Unite de Chimiotherapie, Rue Heger Bordet 1, B 1000, Brussels, Belgium
    Eur J Cancer 36:1755-61. 2000
    ..This paper attempts to critically review to what extent HER2 may improve 'treatment individualisation' for the breast cancer patient...
  6. ncbi request reprint The impact of chemotherapy dose density and dose intensity on breast cancer outcome: what have we learned?
    M J Piccart
    Chemotherapy Unit, Department of Internal Medicine, Institut Jules Bordet, Association Hospitalière de Bruxelles, Centre des Tumeurs de l ULB, 1 rue Héger Bordet, B 1000, Brussels, Belgium
    Eur J Cancer 36:S4-10. 2000
    ..These results represent our current state of knowledge, but clinical trials are being performed to evaluate further the effect of dose intensity, dose density and cumulative dose of key therapeutic agents on patient outcomes...
  7. ncbi request reprint Oxaliplatin or paclitaxel in patients with platinum-pretreated advanced ovarian cancer: A randomized phase II study of the European Organization for Research and Treatment of Cancer Gynecology Group
    M J Piccart
    Institut Jules Bordet and European Organization for Research and Treatment of Cancer, Brussels, Belgium
    J Clin Oncol 18:1193-202. 2000
    ....
  8. doi request reprint Pertuzumab: new hope for patients with HER2-positive breast cancer
    M Capelan
    Department of Medicine, Institute Jules Bordet, l Université Libre de Bruxelles, Brussels, Belgium
    Ann Oncol 24:273-82. 2013
    ..Pertuzumab is a new anti-HER2 humanized monoclonal antibody that prevents the formation of HER2 dimers...
  9. doi request reprint Adjuvant chemotherapy--yes or no? Prognostic markers in early breast cancer
    M J Piccart-Gebhart
    Department of Medicine, Jules Bordet Institute, Brussels, Belgium
    Ann Oncol 18:xii2-7. 2007
    ..Close collaboration between clinicians and scientists will be essential to achieve this goal...
  10. pmc Ki-67 as prognostic marker in early breast cancer: a meta-analysis of published studies involving 12,155 patients
    E de Azambuja
    Medical Oncology Clinic, Jules Bordet Institute, 125 Boulevard de Waterloo, 1000, Brussels, Belgium
    Br J Cancer 96:1504-13. 2007
    ..65-3.91); P<0.001) and node-positive patients (HR=2.33 (95% CI: 1.83-2.95); P<0.001). Our meta-analysis suggests that Ki-67/MIB-1 positivity confers a higher risk of relapse and a worse survival in patients with early BC...